Rivastigmine Patch, Extended Release
NDC Package 70710-1198-7
Package Information
Rivastigmine patches is rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. This formulation utilizes a patch, extended release delivery system. Marketed by Zydus Pharmaceuticals Usa Inc., this product is identified by NDC 70710-1198 and is authorized under FDA application ANDA206318.
Identification & Billing
- RxCUI: 1308569 - rivastigmine 13.3 MG/Day 24HR Transdermal System
- RxCUI: 1308569 - 24 HR rivastigmine 0.554 MG/HR Transdermal System
- RxCUI: 1308569 - rivastigmine 13.3 MG/Day 24HR Transdermal Patch
- RxCUI: 725021 - rivastigmine 4.6 MG/Day 24HR Transdermal System
- RxCUI: 725021 - 24 HR rivastigmine 0.192 MG/HR Transdermal System
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70710 - Zydus Pharmaceuticals Usa Inc.
- 70710-1198 - Rivastigmine
- 70710-1198-7 - 30 POUCH in 1 CARTON / 24 h in 1 POUCH (70710-1198-1)
- 70710-1198 - Rivastigmine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70710-1198-7 identifies a specific commercial package of 30 pouch in 1 carton / 24 h in 1 pouch (70710-1198-1) of Rivastigmine, a human prescription drug labeled by Zydus Pharmaceuticals Usa Inc.. This patch, extended release is formulated for transdermal use and contains rivastigmine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Pharmaceuticals Usa Inc. on March 06, 2019. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. Rivastigmine does not cure either of these diseases, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by restoring the balance of natural substances (neurotransmitters) in the brain.
How is this Zydus Pharmaceuticals Usa Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70710119807. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.